hrp0095p1-590 | Thyroid | ESPE2022

Immunoglobulin Superfamily 1 (IGSF1) Deficiency: A Rare Cause of Isolated Congenital Hypothyroidism in Two Siblings

MacGloin Helen , Bhushan Arya Ved , Schoenmakers Nadia , Buchanan Charles

Introduction: The Newborn Screening Programme (NBS) enables earlier diagnosis of congenital hypothyroidism (CH). However, cases of central congenital hypothyroidism (CCH) are missed in countries which use thyroid stimulating hormone (TSH) based screening strategy. Understanding the pathogenic aetiology of CCH is particularly important because many patients have additional pituitary hormone deficiencies. New genes have been implicated in CCH, including the rece...

hrp0082p2-d3-475 | Hypoglycaemia | ESPE2014

Long-Term Follow Up of Children with Congenital Hyperinsulinism on Octreotide Therapy

Demirbilek Huseyin , Shah Pratik , Arya Ved Bhushan , Hussain Khalid

Background: Octreotide, a long-acting somatostatin analogue, is commonly used in diazoxide unresponsive congenital hyperinsulinism (CHI) patients as a second line medication. However, there are no large studies evaluating long-term follow-up CHI patients on octreotide therapy.Objective and hypotheses: To evaluate the dose range, side effects and long-term follow-up in CHI patients on daily octreotide injections.Method: Twenty-eight...

hrp0097p2-287 | Late Breaking | ESPE2023

Central diabetes insipidus in paediatric cerebral tumors: clinical and radiological features

Criscuolo Sabrina , Partenope Cristina , Bhushan Arya Ved , Albanese Assunta

Introduction: Paediatric brain tumours in the sellar-suprasellar region (SSR) are often associated with central diabetes insipidus (CDI), either at diagnosis caused by the tumour itself or during follow-up as consequence of treatments.Aims: To define the timing of CDI onset and radiological features on brain MRI in our cohort.Methods: We retrospectively analysed paediatric patients...

hrp0095p1-135 | Multisystem Endocrine Disorders | ESPE2022

Hypoaldosteronism without hypocortisolism - an unusual presentation of APECED syndrome

Gounari Eleni , Buchanan Charles , Ghataore Lea , Hannah Romanie , Bushan Arya Ved

Background: Automimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is an extremely rare autoimmune condition caused by AIRE (autoimmune regulator) gene mutations and characterised by a classic triad of 1) chronic mucocutaneous candidiasis, 2) hypoparathyroidism and 3) adrenal insufficiency. APECED can involve any endocrine or non-endocrine organ. Consequently, clinicians need to be mindful of the great variability in presentation. Although ad...

hrp0095p1-191 | Thyroid | ESPE2022

Hyperthyroidism leading to Idiopathic Intracranial Hypertension in a Child – A Case Report

Agrawal Pankaj , R Kapoor Ritika , A Chapman Simon , Wei Christina , R Buchanan Charles , Bhushan Arya Ved

Introduction: Idiopathic intracranial hypertension (IIH) is a rare neurological condition characterized by raised intracranial pressure (ICP) in the absence of hydrocephalus, brain parenchymal lesion, vascular malformation, or central nervous system (CNS) infection. Hyperthyroidism is a rare but known cause of raised ICP in children and adults, with only a few case reports in the paediatric population. We describe a 7-year-old boy with IIH associated with hype...

hrp0092p2-231 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Macroprolactinoma Presenting with Pituitary Apoplexy Associated with Middle Cerebral Artery Infarction in an Adolescent Male

Newbold Sally , Arya Ved Bushan , Kapoor Ritika , Thomas Nick , Fox Krystal , Aylwin Simon , Buchanan Charles

Background: Pituitary apoplexy is a clinical syndrome caused by haemorrhage of the pituitary gland, typically characterised by acute confusion, headache, vomiting and visual disturbance. It is regarded as a medical emergency. It is rare in childhood and adolescence, occurring in association with pituitary tumours. We report an unusual case of pituitary apoplexy associated with a cerebral infarction secondary to internal carotid artery compression.<p class=...

hrp0082p2-d3-474 | Hypoglycaemia | ESPE2014

Plasma Glucagon and Somatostatin Levels in Children with Congenital Hyperinsulinism During Hypoglycaemia

Shah Pratik , Mamikunian Gregg , Gilbert Clare , Morgan Kate , Hinchey Louise , Arya Ved , Demirbilek Huseyin , Hussain Khalid

Background: Congenital hyperinsulinism (CHI) causes severe hypoglycaemia in children, due to dysregulated insulin secretion from pancreatic β-cells. Glucagon, secreted from the pancreatic α-cells, is critical for blood glucose homeostasis. Somatostatin is secreted by Δ-cells of the islets and by extraislet neuroendocrine cells. Exogenous somatostatin potently inhibits insulin and glucagon release from pancreatic islets. Under normal physiological conditions, low...

hrp0084p1-103 | Perinatal | ESPE2015

Molecular Characterization of a Novel Non-stop KCNJ11 Mutation Associated with a Dual Focal and Diffuse Hyperinsulinaemic Hypoglycaemia Phenotype

Arya Ved Bhushan , Aziz Qadeer , Flanagan Sarah E , Ellard Sian , Tinker Andrew , Hussain Khalid

Background: Hyperinsulinaemic hypoglycaemia (HH) has two main histological subtypes: diffuse and focal. Diffuse HH are most commonly due to recessive or dominant ABCC8/KCNJ11 mutations. Focal HH results due to somatic loss of the maternal 11p allele involving the ABCC8 and KCNJ11 region in patients with paternally inherited ABCC8 or KCNJ11 mutation.Aim: To molecular characterise a novel non-stop KCNJ11</em...

hrp0097p1-90 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Low-Dose Diazoxide Therapy in Hyperinsulinaemic Hypoglycaemia

Yi-Lin Ng Amy , Agarwal Pankaj , Vijayan Roopa , B Arya Ved , R Kapoor Ritika , Shah Pratik

Background: Diazoxide therapy is used as first line treatment in hyperinsulinaemic hypoglycaemia (HH). Apart from a single study reporting efficacy of low dose diazoxide in small for gestational age (SGA) infants, diazoxide has been reported to be used in doses of 5-20 mg/kg/day [1].Objective: To report the outcomes of infants with HH responsive to low dose diazoxide (≤5mg/kg/day).Method...

hrp0097p1-191 | Thyroid | ESPE2023

Paediatric Graves’ Disease: Presentation, Treatment and Follow up. A Single Centre Experience from United Kingdom.

Vijayan Roopa , Kapoor Ritika , Agrawal Pankaj , Buchanan Charles , Chapman Simon , Arya Ved

Objective: To describe a cohort with paediatric Graves disease followed between 2012 and 2022 at King’s College Hospital, London.Materials and Methods: Retrospective study of 36 patients treated with block and replace regimen of anti-thyroid drugs with a median (range) follow up of 4.25 (1.1-10.8) years. Demographic, clinical, biochemical and treatment data were collected from clinical records. Predictive factors f...